Ocumetics Welcomes Dr. Doyle Stulting and Dr. Bart McRoberts to Board of Directors

Ocumetics Welcomes Dr. Doyle Stulting and Dr. Bart McRoberts to Board of Directors

(TheNewswire)

Calgary, Alberta TheNewswire - September 1, 2023 - Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in advanced eye care solutions, is pleased to announce the appointment of Dr. Doyle Stulting and Dr. Bart McRoberts to its Board of Directors. With their unparalleled expertise in ophthalmology and vision research, Drs. Stulting and McRoberts bring a wealth of knowledge that will help drive Ocumetics' innovation and commitment to improving eye care globally.

Dr. Robert Doyle Stulting has authored over 250 papers in peer-reviewed journals, published several textbook chapters, taught courses for over 30 years at the American Academy of Ophthalmology, and lectured around the world.  He was awarded the American Academy of Ophthalmology's Lifetime Achievement Award and the FDA's Citation for Excellence, Commitment, and Outstanding Service in Protecting the Public.  Dr. Stulting has served as the Corporation's Chief Medical Officer since October 1, 2021.

Dr. James Barton McRoberts received his Doctorate in Optometry in 1974 from the University of Waterloo. He has managed a private clinical practice since 1974 in both Squamish and West Vancouver.  Dr. McRoberts brings a vast array of experience to Ocumetics.  Among other things, he has functioned as the professional services director of The Laser Center in Vancouver, the VP and a board member of Optometric Services Ltd. Montreal and as the President of the British Columbia Association of Optometrists.  Dr. McRoberts has also served as the Registrar and Deputy Registrar for the College of Optometrists.

"Dr. Stulting and Dr. McRoberts are renowned figures in the field of eyecare, and their visionary contributions will undoubtedly propel Ocumetics to new heights," commented Dr Garth Webb, Chairman of Ocumetics. "Their presence on our board reinforces our dedication to enhancing visual health and revolutionizing the way we approach eye care."

"As Ocumetics continues to push the boundaries of eye care, the addition of these accomplished professionals solidifies the company's mission to create a brighter, clearer future for individuals worldwide," adds Dean Burns, President and CEO of Ocumetics.

About Ocumetics

Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that specializes in adaptive lens designs.  Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye's natural muscle activity to shift focus from distance to near.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns

President and CEO

(817) 874-7564

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2023 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

OTC:CA
The Conversation (0)
Ocumetics Technology

Ocumetics Technology

Pioneering Vision Enhancement with the Ocumetics Accommodating Lens

Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

(TheNewswire) Calgary, Alberta May 24, 2024 - TheNewswire . Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation... Keep Reading...
Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

(TheNewswire) Calgary, Alberta TheNewswire - May 15, 2024. Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face... Keep Reading...
Ocumetics Technology Corp  To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

Ocumetics Technology Corp To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

(TheNewswire) Calgary, Alberta TheNewswire - February 29, 2024 - Ocumetics Technology Corp. ("Ocumetics") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research. Martin Gagel of Market Radius... Keep Reading...
Ocumetics Announces Extension of Private Placement

Ocumetics Announces Extension of Private Placement

(TheNewswire) Calgary, Alberta TheNewswire - December 21, 2023 - Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that the TSX Venture Exchange has granted a 15-day extension to close the Corporation's non-brokered private... Keep Reading...
Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

(TheNewswire) Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Latest Press Releases

Related News